Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute Trial AB01

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8322-8330

  Langley, Ruth E ^a   Carmichael, James ^a   Jones, Alison L ^a   Cameron, David A ^a   Qian, Wendi ^a   Uscinska, Barbara ^a   Howell, Anthony ^a   Parmar, Mahesh ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CHLORPHENIRAMINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; BREAST TUMOR; COMPARATIVE STUDY; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33644680299     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.1817     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics. CA Cancer J Clin 54:8-29, 2004
2. Cancer Research UK: Cancer mortality, 2004. www.cancerresearchuk.org
3. Winer EP, Morrow M, Osbourne CK, et al: Malignant tumors of the breast, in DeVita VT, Hellman S, Rosenburg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott Williams and Wilkins, 2001, pp 1699
4. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
5. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent vs. continuous and of Adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: A Cancer and Leukemia Group B study. Am J Clin Oncol 7:231-239, 1984
6. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: A CALGB study-Cancer and Leukemia Group B. J Clin Oncol 5:1523-1533, 1987
7. Ackland SP, Anton A, Breitbach GP, et al: Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study. J Clin Oncol 19:943-953, 2001
8. Andersson M, Madsen EL, Overgaard M, et al: Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer: A randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Eur J Cancer 35:39-46, 1999
9. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460, 1998
10. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
11. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
12. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
13. Fumoleau P, Chevallier B, Kerbrat P, et al: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996
14. Ravdin PM, Burris HA III, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
15. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7:687-693, 1996
16. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
17. Gianni L, Vigano L, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915, 1997
18. Hortobagyi GN, Willey J, Rahman Z, et al: Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24:517-65-317-68, 1997 (suppl 17)
19. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin-paclitaxel: A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients-Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 97:40-45, 2003
20. Conte PF, Baldini E, Gennari A, et al: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510-2517, 1997
21. Luck HJ, Thomssen C, du Bois BA, et al: Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semm Oncol 17:S17-35-S17-39, 1997 (suppl 17)
22. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19:197-228, 1993
23. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial J Clin Oncol 20:3114-3121, 2002
24. Jassem J, Pienkowski T, Pluzanska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715, 2001
25. Luch HJ, Thomssen C, Untch M, et al: Multicenter phase III study in first-line treatment of advanced breast cancer (ABCI: Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC)-A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 19:73a, 2000 (abstr 280)
26. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342 J Clin Oncol 22:2061-2068, 2004
27. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
28. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17:2355-2364, 1999
29. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18:724-733, 2000
30. Mackey JR, Paterson A, Dinix LY, et al: Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35a, 2002 (abstr 137)
31. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975, 2003
32. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517-1526, 2004
33. Henderson CI, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003